1Bamon G. Sur le pouvoir floculant et sur les proprietes immunisantes dune oxin diphterique rendue anatoxique (anatoxine) [J].C R Acad Sci 1923,177: 1338-1340.
2Ramon G, Zoeller C. Lanntoxine tetanique et I'immunisation active de I'homme vis-a-vis du tetanco[J]. Ann Inst Pasteur Paris 1927,41:803-833.
3Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface-antigen particles in yeast[J]. Nature 1982,298:347-350.
4Bumette WN, Samai B, Browne J, et al. Properties and relative immunogenicity d various preparations of recombinant DNA-derived hepatitis B surface antigen[J]. Dev Biol Stand 1985,59:113-120.
5Thanavala Y, Yang YF, Lyons P, et al. Immunogenicity of transgenic plant-derived hepatitis B surface antigen [J]. Proc Natl Acad Sci USA 1995,92:3358-3361.
6Pizza M, Covacci A, Bartoloni A, et al. Mutants of pertussis toxin suitable for vaccine development [J]. Science 1989,246: 497-500.
7Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation[J]. Vaccine 1995,13 1509-1514.
8Van Hoecke C, Comberbach M, De Grave D, et al. Evaluation of the safety,reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults[J]. Vaccine 1996,14:1620-1626.
9Orentas B J, Hildreth JE, Obah E, et al. Induction of CD4 + human cytolytic T-cells specific for HlV-infected cells by a gp160 subunit vaccine[J]. Science 1990,248 : 1234-1237.
10Bennan PW, Gregory TJ, Riddle L, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glyc.oprotein gp120 but not gp160[J]. Nature 1990,345:622-625.
